https://www.treatlyme.net/guide/treat-persister-lyme-works
How to Treat Persister Lyme & Bartonella
By Dr. Marty Ross

I provide a large part of the information in this article in A Lyme Disease Antibiotic Guide and in Kills Bartonella: A Brief Guide. I am including this information as a stand-alone article on persisters for those looking for information just on this topic and additional persister treatment options from those I lay out in the Lyme and Bartonella articles.
Marty Ross MD
About Persister Lyme & Bartonella
There are many reasons Lyme and Bartonella are hard to treat. One reason is persister Lyme and Bartonella germs ignore standard antibiotics. Based on numerous laboratory experiments since 2015, the Lyme germ is shown to have a growth state and a hibernating – non-growing state. These hibernators are called persisters. They do not respond to regular prescription antibiotics – although they do seem to respond to many herbal antibiotics that we use.
More recently – experiments starting in late 2019 from Ying Zhang, MD and his colleagues, show that Bartonella also has persister forms. (See link for article)
__________________
SUMMARY of treatments Dr. Ross uses for Lyme and/or Bartonella persisters:
- Disulfiram
- Methylene Blue
- Cefuroxime plus Clarithromycin plus Nitazonxanide
- Oregano, Cinnamon, and Clove oils
- Japanese knotweed
- Cat’s claw
- Azlocillin
I highly recommend reading Ross’ entire article as there are many nuances within it including Dr. Burrascano‘s use of cycling. He and numerous patients achieved remission using this approach and current research appears to support the practice. Not only is cycling effective, it gives the body, particularly the gut, a much needed break from harsh antibiotics.
For more:
- https://madisonarealymesupportgroup.com/2016/02/13/lyme-disease-treatment/
- https://madisonarealymesupportgroup.com/2016/01/03/bartonella-treatment/
- https://madisonarealymesupportgroup.com/2019/05/05/good-news-for-bartonella-patients-identification-of-fda-approved-drugs-with-higher-activity-than-current-front-line-drugs/